Alessandra Raimondi

Alessandra Raimondi

Auto-generated profile, based on publicly available information

Alessandra Raimondi

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FPFilippo Pietrantonio
Filippo Pietrantonio
RMRosalba Miceli
Rosalba Miceli
ARAlessandra Raimondi
Alessandra Raimondi
YKYoung Woo Kim
Young Woo Kim
WKWon Ki Kang
Won Ki Kang
ESElizabeth Catherine Smyth
Elizabeth Catherine Smyth
PURPOSE: In the CLASSIC and MAGIC trials, microsatellite instability (MSI)–high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer (GC). Given the low prevalence of MSI-high status in GC and its association with other positive prognostic variables, large data sets are needed to draw robust evidence of its prognostic/predictive value. PATIENTS AND METHODS: We performed a multinational, individual-patient-data meta-analysis of the prognostic/predictive role of MSI in patients with resectable GC enrolled in the MAGIC, CLASSIC, ARTIST, and ITACA-S trials. Prognostic analyses used multivariable Cox models (MVM). The predictive role of MSI was assessed both in an all-comer population and in MAGIC and CLASSIC trials by MVM testing of the interaction of treatment (chemotherapy plus surgery v surgery) with MSI. RESULTS: MSI status was available for 1,556 patients: 121 (7.8%) had MSI-high status; 576 were European, and 980 were Asian. In MSI-high versus MSI-low/microsatellite stable (MSS) comparisons, the 5-year disease-free survival (DFS) was 71.8% (95% CI, 63.8% to 80.7%) versus 52.3% (95% CI, 49.7% to 55.1%); the 5-year overall survival (OS) was 77.5% (95% CI, 70.0% to 85.8%) versus 59.3% (95% CI, 56.6% to 62.1%). In MVM, MSI was associated with longer DFS (hazard ratio [HR], 1.88; 95% CI, 1.28 to 2.76; P < .001) and OS (HR, 1.78; 95% CI, 1.17 to 2.73; P = .008), as were pT, pN, ethnicity, and treatment. Patients with MSI-low/MSS GC benefitted from chemotherapy plus surgery: the 5-year DFS compared with surgery only was 57% versus 41% (HR, 0.65; 95% CI, 0.53 to 0.79), and the 5-year OS was 62% versus 53% (HR, 0.75; 95% CI, 0.60 to 0.94). Conversely, those with MSI-high GC did not: the 5-year DFS was 70% versus 77% (HR, 1.27; 95% CI, 0.53 to 3.04), and the 5-year OS was 75% versus 83% (HR, 1.50; 95% CI, 0.55 to 4.12). CONCLUSION: In patients with resectable primary GC, MSI is a robust prognostic marker that should be adopted as a stratification factor by clinical trials. Chemotherapy omission and/or immune checkpoint blockade should be investigated prospectively in MSI-high GCs according to clinically and pathologically defined risk of relapse.

3 April 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
OGon behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group
on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group
EVElena Verzoni
Elena Verzoni
GCGiacomo Cartenì
Giacomo Cartenì
ECEnrico Cortesi
Enrico Cortesi
DGDiana Giannarelli
Diana Giannarelli
GPGiuseppe Procopio
Giuseppe Procopio
Background The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. Methods Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3 mg/kg every 2 weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The association between overall survival (OS) and irAEs was assessed, and associations between variables were evaluated with a logistic regression model. Results A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% CI 3.7–6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3–4 drAEs were reported in 124 (32%) and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%) of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than those without drAEs (median OS 22.5 versus 16.4 months, p = 0.01). Pts with irAEs versus without irAEs had a more significant survival benefit (median OS not reached versus 16.8 months, p = 0.002), confirmed at the landmark analysis at 6 weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p = 0.003) and multivariable (HR 0.57, p = 0.02) analysis. Conclusions The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts treated with nivolumab.

1 January 2019 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
FCFrancesca Corti
Francesca Corti
FNFederico Nichetti
Federico Nichetti
ARAlessandra Raimondi
Alessandra Raimondi
MNMonica Niger
Monica Niger
NPNatalie Prinzi
Natalie Prinzi
SPSara Pusceddu
Sara Pusceddu

1 September 2019 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
FPFilippo Pietrantonio
Filippo Pietrantonio
FMFederica Morano
Federica Morano
SCSalvatore Corallo
Salvatore Corallo
RMRosalba Miceli
Rosalba Miceli
SLSara Lonardi
Sara Lonardi
FBFilippo de Braud
Filippo de Braud
The treatment landscape of unresectable metastatic colorectal cancer (mCRC) has relevantly changed after the introduction of biological agents and the development of continuum of care strategies. The decision-making process on the optimal intensity and duration of first-line treatment in patients with mCRC is based on literature data, treatment tolerability, patients’ preferences, and costs.1

27 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GRGiovanni Randon
Giovanni Randon
GFGiovanni Fucà
Giovanni Fucà
DRDaniele Rossini
Daniele Rossini
ARAlessandra Raimondi
Alessandra Raimondi
FPFilippo Pagani
Filippo Pagani
FPFilippo Pietrantonio
Filippo Pietrantonio
Tumors bearing homologous recombination deficiency are extremely sensitive to DNA double strand breaks induced by several chemotherapeutic agents. ATM gene, encoding a protein involved in DNA damage response, is frequently mutated in colorectal cancer (CRC), but its potential role as predictive and prognostic biomarker has not been fully investigated. We carried out a multicenter effort aimed at defining the prognostic impact of ATM mutational status in metastatic CRC (mCRC) patients. Mutational profiles were obtained by means of next-generation sequencing. Overall, 35 out of 227 samples (15%) carried an ATM mutation. At a median follow-up of 56.6 months, patients with ATM mutated tumors showed a significantly longer median overall survival (OS) versus ATM wild-type ones (64.9 vs 34.8 months; HR, 0.50; 95% CI, 0.29–0.85; P = 0.01). In the multivariable model, ATM mutations confirmed the association with longer OS (HR, 0.57; 95% CI, 0.33–0.98; P = 0.04). The prognostic impact of ATM mutations was independent from TP53 mutational status and primary tumor location. High heterogeneity score for ATM mutations, possibly reflecting the loss of wild-type allele, was associated with excellent prognosis. In conclusion, we showed that ATM mutations are independently associated with longer OS in patients with mCRC.

1 March 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CVClaudio Vernieri
Claudio Vernieri
FNFederico Nichetti
Federico Nichetti
ARAlessandra Raimondi
Alessandra Raimondi
SPSara Pusceddu
Sara Pusceddu
MPMarco Platania
Marco Platania
FBF. De Braud
F. De Braud